The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
here is the link to IFU 11 which is mentioned in the CTDA protocol spreadsheet
https://www.primerdesign.co.uk/assets/files/path_promate_covid_19_ce_sted_ifu_issue_11_00.pdf?timestamp=1649387360
PROmate q32 just been added to CTDA list
https://twitter.com/Larry64450205/status/1513528557733089281
https://www.gov.uk/government/publications/covid-19-test-validation-approved-products?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e9ac3df4-121c-4c48-9b2d-726ad3b008b8&utm_content=immediately#full-publication-update-history
Spotted by larry and growhydrodude1
https://www.theyworkforyou.com/wrans/?id=2022-03-03.133999.h&s=Pcr+testing+in+the+nhs#g133999.q0
Direct link. Looks like moving from national contract to individual trust requirements
"This event is taking place this week in Birmingham, but I can't find Novacyts name on the list of exhibitors.
https://congress.ibms.org/ibms-congress-2022/programme.html
Were they a late entry to the event?"
Exmex, they were at the 2019 IBMS congress exhibition. It's odd that they go to exhibitions abroad but don't attend the IBMS congress. I can only fathom a guess that they didn't attend due to the on-going dispute
It was mentioned that revenue from Covid sales may be reduced by 50% in 2022.
See the outlook below taken from the RNS on 25th Jan 2022
https://www.lse.co.uk/rns/NCYT/strategy-and-full-year-2021-trading-update-qgoeql7ul3x7i26.html
"2022 outlook
As observed over the last two years, and highlighted in the last two months, the course of this pandemic is unpredictable and so, therefore, is the predictability of testing demand. Currently, the Board expects COVID-19 reported sales could be reduced by around 50% in 2022, versus 2021, which will be partially offset by new non-COVID-19 products which will start to come onstream in Q4 2022."
thanks for that link Kaeren, Really interesting. You can play around with the filters. here are 2
https://www.volza.com/imports-global/global-import-data-of-genesig
https://www.volza.com/imports-global/global-import-data-of-primer+design-primerdesign
Thanks to larry for spotting the CTDA update and posting this on twitter
https://twitter.com/Larry64450205/status/1496885787459264513
New Forms Research has also posted screenshots of the list of tests.
The protocol has been updated today which will be effective from 1st March 2022 and continue until 31st May 2022.
https://www.gov.uk/government/publications/covid-19-test-validation-approved-products
https://www.gov.uk/government/publications/covid-19-test-validation-approved-products/medical-devices-regulations-2002-protocols-effective-from-1-march-2022
here is the list of current approved lft tests which have passed phase 3a. biosynx is there
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/outcome-of-the-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices
as at 10 February 2022, Biosynex's holding in the Company on a voting and capital basis is 3.0012% (2,119,627 shares)
as at 14 February 2022, Biosynex's holding in the Company on a voting and capital basis is 4.04% (2,855,959 shares)
no times are given but thats 3 trading days. They could well be over 5% right now if they are continuing their buying at a similar rate.
was reported 30-nov-21 that biosynex held 18.82% of theradiag's share capital
https://www.businesswire.com/news/home/20211129005813/en/THERADIAG-notes-the-acquisition-of-a-stake-in-its-capital-by-BIOSYNEX
was reported on 13-jan-22 that theradiag and biosynex have signed a distribution agreement
https://www.businesswire.com/news/home/20220112005904/en/Theradiag-Signing-of-a-Distribution-Agreement-with-BIOSYNEX-of-Their-AMPLIQUICK-SARS-CoV-2-PCR-Test
Could they be looking to something similar. Joint projects?
From the link that larry posted - http://novacyt.com/wp-content/uploads/2017/10/Admission-Document-Novacyt-18-October-2017.pdf
Page 36 - 19 Takeover code
Thats from 2017
From this link (2020) - https://uk.practicallaw.thomsonreuters.com/4-502-1646?transitionType=Default&contextData=(sc.Default)&firstPage=true#co_anchor_a746342
There is a section on mandatory offers which is 30% threshold
"The mandatory tender offer price must be at least the highest price paid by the bidder for securities of the target during the 12-month period preceding the crossing of the 30% threshold."
I think someone else alluded to this earlier, sorry I wasn't able to recall who from.
Thanks Larry10, that clears that up :)
Here are a couple of links regarding M&A activity
https://www.lexology.com/library/detail.aspx?g=64926d2e-cc8e-448b-bf7d-04579394b9f5
https://uk.practicallaw.thomsonreuters.com/4-502-1646?transitionType=Default&contextData=(sc.Default)&firstPage=true#co_anchor_a746342
SAGE have released a paper on viral evolution scenarios.
Here is the link which you can view the pdf from
https://www.gov.uk/government/publications/academics-viral-evolution-scenarios-10-february-2022
"In each scenario, it is assumed that a relatively stable, repeating pattern is reached over time (2-10 years) but it is likely that the transition to this will be highly dynamic and unpredictable. It may not be possible to know with confidence from what happens in the next 12-18 months which long-term pattern will emerge. "
"Surveillance, vaccines, therapeutics and testing will also have large impacts on outcomes"
"Access to testing has also been key for reducing transmission and is likely to impact the shape and duration of any future waves"
Well researched larry has provided these links on twitter (thank you!). Sharing them for the LSE/NCYT board to view.
The guidance for desktop review has been updated 10/2/22
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/covid-19-test-approval-step-2-process-for-desktop-review
It's quite a read however here is a quick quote
"Where a test has already been validated by the Technologies Validation Group (TVG), the applicant can make a request to use the TVG data for the purposes of the CTDA application. Please email your request for data"
On the same day there were discussions in the lords
https://hansard.parliament.uk/Lords/2022-02-10/debates/FC1526E9-4CD9-49BB-9641-9558B57CDD2F/Covid-19LateralFlowTests
BIVDA have released a statement on 4/2/22
https://bivdanewsletter.com/membership-news/covid-19-desktop-validation-bivda-update-3/
"There have been a number of approvals which are set to be released imminently, so members should review the approved list which can be found at CTDA – approved-products
Over the Christmas period, most suppliers have provided the outstanding requested information and those are still in the evaluation stages"
Hopefully should see some (fingers crossed positive) movement for the outstanding tests from novacyt waiting on CTDA approval.
Exmex,
Here is the link with the atamis urls
https://bidstats.uk/tenders/2020/W47/739312011